Unibest

Pharmaceutical intermediates

Vibegron Intermediates

6 pharmaceutical intermediates for Vibegron. Indication: Overactive Bladder; Urinary Incontinence.

提交项目All intermediates

About Vibegron

Originator
Merck & Co Inc; Roivant Sciences Inc
Indication
Overactive Bladder; Urinary Incontinence
Approved Date
12/23/2020
NCE Patent
12/23/2025
DS/DP
04/02/2029

Available intermediates

6 intermediates currently listed for Vibegron. Request specifications, documentation or a quotation for any item below.

Vibegron intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMidine-6-carboxylic acid1190392-22-3//
tert-butyl(4-(3-(dimethoxyphosphoryl)-2-oxopropyl)phenyl)carbamate494224-44-1//
(1R,2R)-2-amino-6-(4-nitrophenyl)-1-phenylhex-5-yn-1-olhydrochloride1628836-08-7//
(R)-((2R,5S)-5-(4-aminobenzyl)pyrrolidin-2-yl)(phenyl)methanol1295539-30-8//
tert-butyl(4R,5R)-4-(hydroxymethyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate1009092-91-4//
tert-butyl(4R,5R)-4-((E)-4-(4-((tert-butoxycarbonyl)amino)phenyl)-3-oxobut-1-en-1-yl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate1426235-01-9//

Other programs under V

Valbenazine Tosylate (NBI-98854)Varenicline TartrateVelpatasvirVenetoclaxVericiguatVilazodone HydrochlorideVONOPRAZAN FUMARATEVoxelotor

Building toward Vibegron?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →